Hemingway Capital and CVF Capital Partners Invest in Vege Labs

Hemingway Capital Acquires Vege-Kurl, Inc. (Vege Labs)

March 12, 2021

Consumer Products

Hemingway Capital has acquired Vege-Kurl, Inc. (operating as Vege Labs and subsidiary Joar Labs), a Glendale, California-based private-label manufacturer of personal care, cosmetic and household products. Founders/executives Eric Huffman and Joe Desens sold the business to pursue retirement; CVF Capital Partners provided acquisition and expansion financing and a seasoned industry executive will assume the CEO role.

Ampersand Capital Partners Makes Growth Investment in VIVEbiotech

December 4, 2024

Biotechnology

Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.

Hemingway Capital Leads Recapitalization of GTA Containers; Parkway Capital and Farragut Invest

March 15, 2022

Manufacturing

Hemingway Capital led a recapitalization of GTA Containers, LLC, partnering with the company's senior management. Parkway Capital and Farragut Capital Partners each provided subordinated debt and equity to support the transaction and to back GTA's growth and product expansion initiatives.

Vopne Capital Provides Growth Capital to Coastal Manufacturing

January 18, 2023

Manufacturing

Vopne Capital made a growth capital investment in Coastal Manufacturing to support the company's next stage of expansion and innovation. Coastal Manufacturing, headquartered in Watsonville, California and founded by Mark Hoffseth, designs and manufactures food processing equipment for leafy greens, vegetables, frozen fruits and confectionery markets.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

CVC Funds Takes Minority Stake in Hempel A/S

May 8, 2024

Manufacturing

CVC Funds will subscribe to new shares in Hempel A/S via its Strategic Opportunities platform to acquire a minority stake of up to 30%, with the Hempel Foundation remaining the majority owner. The investment is intended to accelerate Hempel’s organic and inorganic growth — including R&D in sustainable coating technologies and potential M&A — and is expected to close in the second half of 2024 subject to regulatory approval.